Neither the TM6SF2 E167K polymorphism nor the PNPLA3 I148M polymorphism alone can fully account for the molecular genetic mechanisms of NAFLD or disease risk. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.